+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Leber Congenital Amaurosis (LCA) - Pipeline Review, H2 2018

  • ID: 4622992
  • Drug Pipelines
  • 66 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Allergan Plc
  • MeiraGTx Holdings Plc
  • Novelion Therapeutics Inc
  • Ophthotech Corp
  • ProQR Therapeutics NV
  • Spark Therapeutics Inc
  • MORE
Leber Congenital Amaurosis (LCA) - Pipeline Review, H2 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Leber Congenital Amaurosis (LCA) - Pipeline Review, H2 2018, provides an overview of the Leber Congenital Amaurosis (LCA) (Genetic Disorders) pipeline landscape.

Leber congenital amaurosis is an eye disorder that primarily affects the retina, which is the specialized tissue at the back of the eye that detects light and color. This condition is the most common cause of inherited blindness in childhood. Symptoms include vision loss, roving eye movements, deep-set eyes, developmental delay, epilepsy, and motor skill impairment.

Report Highlights:

This latest pipeline guide Leber Congenital Amaurosis (LCA) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Leber Congenital Amaurosis (LCA) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Leber Congenital Amaurosis (LCA) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Leber Congenital Amaurosis (LCA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 1, 2 and 3 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 3 molecules, respectively.

Leber Congenital Amaurosis (LCA) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Leber Congenital Amaurosis (LCA) (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Leber Congenital Amaurosis (LCA) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Leber Congenital Amaurosis (LCA) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Leber Congenital Amaurosis (LCA) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Leber Congenital Amaurosis (LCA) (Genetic Disorders)
Reasons to buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Leber Congenital Amaurosis (LCA) (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Leber Congenital Amaurosis (LCA) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Allergan Plc
  • MeiraGTx Holdings Plc
  • Novelion Therapeutics Inc
  • Ophthotech Corp
  • ProQR Therapeutics NV
  • Spark Therapeutics Inc
  • MORE
Introduction

Report Coverage

Leber Congenital Amaurosis (LCA) - Overview

Leber Congenital Amaurosis (LCA) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Leber Congenital Amaurosis (LCA) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Leber Congenital Amaurosis (LCA) - Companies Involved in Therapeutics Development

Allergan Plc

MeiraGTx Holdings Plc

Novelion Therapeutics Inc

Ophthotech Corp

ProQR Therapeutics NV

Spark Therapeutics Inc

Leber Congenital Amaurosis (LCA) - Drug Profiles

A-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EDIT-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate AIPL1 for Leber’s Congenital Amaurosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate AIPL1 for Ophthalmology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Retinal Guanylyl Cyclase-1 for Leber Congenital Amaurosis-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate RPE65 for Leber Congenital Amaurosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate RPE65 for Leber Congenital Amaurosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Replace CEP290 for Leber Congenital Amaurosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QR-110 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

voretigene neparvovec - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

zuretinol acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Leber Congenital Amaurosis (LCA) - Dormant Projects

Leber Congenital Amaurosis (LCA) - Product Development Milestones

Featured News & Press Releases

Aug 27, 2018: Editas Medicine announces transition of chief medical officer

Aug 16, 2018: Editas Medicine Announces the Completion of the Recombinant DNA Advisory Committee (RAC) Registration Process

May 18, 2018: Editas Medicine Reports Data Demonstrating Subretinal Injection of EDIT-101 Well-tolerated in Non-human Primates

Mar 26, 2018: Boy with Inherited Blindness First to Receive FDA-Approved Gene Therapy at Bascom Palmer

Mar 21, 2018: Childrens Hospital Los Angeles Treats First Patient on the West Coast Using Gene Therapy

Jan 03, 2018: Spark's Gene Therapy Treatment for Blindness LUXTURNA to Cost $850,000

Oct 19, 2017: Editas Medicine Demonstrates Dose-Dependent, In Vivo Editing with EDIT-101 in CEP290 Transgenic Mice

Sep 26, 2017: Editas Medicine Receives EMA's Orphan Medicinal Product Designation for EDIT-101 for the Treatment of LCA10

Sep 12, 2017: Editas Medicine Initiates Clinical Natural History Study to Evaluate Patients with Leber Congenital Amaurosis Type 10

Jul 31, 2017: Spark Therapeutics Submits Marketing Authorization Application to European Medicines Agency for Investigational LUXTURNA (voretigene neparvovec)

Jan 09, 2017: Editas Medicine Reports on Recent Progress and 2017 Goals at J.P. Morgan Healthcare Conference

Apr 27, 2016: Editas Medicine Announces Presentations at Upcoming Scientific Conferences

May 04, 2015: Penn Study Indicates that Gene Therapy Efficacy for LCA is Dynamic: Improvement is Followed by Decline in Vision

May 01, 2015: Spark Therapeutics to Have Multiple Presentations at 2015 ARVO Meeting

Dec 05, 2014: QLT Announces Results From Proof-of-Concept Trial With Oral Synthetic cis-Retinoid (QLT091001) in Adult Subjects With Impaired Dark Adaptation and/or Impaired Low Luminance Vision

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Leber Congenital Amaurosis (LCA), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Leber Congenital Amaurosis (LCA) - Pipeline by Allergan Plc, H2 2018

Leber Congenital Amaurosis (LCA) - Pipeline by MeiraGTx Holdings Plc, H2 2018

Leber Congenital Amaurosis (LCA) - Pipeline by Novelion Therapeutics Inc, H2 2018

Leber Congenital Amaurosis (LCA) - Pipeline by Ophthotech Corp, H2 2018

Leber Congenital Amaurosis (LCA) - Pipeline by ProQR Therapeutics NV, H2 2018

Leber Congenital Amaurosis (LCA) - Pipeline by Spark Therapeutics Inc, H2 2018

Leber Congenital Amaurosis (LCA) - Dormant Projects, H2 2018

List of Figures

Number of Products under Development for Leber Congenital Amaurosis (LCA), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Allergan Plc
  • MeiraGTx Holdings Plc
  • Novelion Therapeutics Inc
  • Ophthotech Corp
  • ProQR Therapeutics NV
  • Spark Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4622992
Adroll
adroll